Abstracts tagged "ANCA associated vasculitis"

Abstract Number: LB16 • ACR Convergence 2025
Mepolizumab Reduces End-Organ Manifestations Compared with Standard of Care in Patients with EGPA and HES: A US Real-world Analysis
David Silverman¹, Timothy Barnes², Nnaemeka Odo², Jared Silver³, Lisa Le², Amy Edgecomb⁴ and Hitesh Patel⁵, ¹Rheumatology Department, Kaiser Permanente Colorado Medical Group, Denver, Colorado, ²Value and Evidence Solutions, Optum Life Sciences, Eden Prairie, Minnesota, ³Clinical Development, Amgen, Thousand Oaks, California, ⁴Anti-infectives and Respiratory, GSK, Philadelphia, Pennsylvania, ⁵US Medical Affairs, GSK, Durham, North Carolina
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) and hypereosinophilic syndrome (HES) are rare systemic diseases characterized by persistent eosinophilia and tissue infiltration, resulting in end-organ dysfunction…
Abstract Number: 2515 • ACR Convergence 2025
The Association Between Neurologic Involvement and Cumulative Damage in ANCA-Associated Vasculitis
Ruoning Ni¹, Jessica L. Bloom², Kaci Pickett-Nairne², Lori Silveira³, Chao Zhang⁴, David Cuthbertson⁵, Thomas corbridge⁶, Nader Khalidi⁷, Curry Koening⁸, Carol McAlear⁹, Paul Monach¹⁰, Larry Moreland¹¹, Christian Pagnoux¹², Rennie Rhee⁹, Philip Seo¹³, Jared Silver⁶, Ulrich Specks¹⁴, Kenneth Warrington¹⁴, Michael Wechsler¹⁵, Carol Langford¹⁶, Peter Merkel⁹ and Rula Hajj-Ali¹, ¹Cleveland Clinic, Cleveland, ²University of Colorado, Denver, ³University of Colorado, Aurora, CO, ⁴Cleveland Clinic, Cleveland Heights, OH, ⁵University of South Florida, Tampa, ⁶US Medical Affairs Respiratory GSK, Durham, ⁷Department of Medicine, McMaster University and St. Joseph’s Healthcare, Hamilton, Canada, ⁸University of Texas Dell Medical School, Austin, TX, ⁹University of Pennsylvania, Philadelphia, PA, ¹⁰VA Boston Healthcare System, Boston, MA, ¹¹University of Colorado, Denver, CO, ¹²Mount Sinai Hospital, University Health Network, Toronto, and Canadian Vasculitis Research Network (CanVasc), Toronto, ON, Canada, ¹³Johns Hopkins University, Baltimore, MD, ¹⁴Mayo Clinic, Rochester, MN, ¹⁵Department of Medicine, National Jewish Health, Denver, ¹⁶Cleveland Clinic, Moreland Hills, OH
Background/Purpose: Neurologic involvement (NI) is common in ANCA-associated vasculitis (AAV) and often irreversible. It is unknown whether patients with AAV and NI accumulate more damage…
Abstract Number: 1765 • ACR Convergence 2025
Maintenance of remission with rituximab versus azathioprine in newly diagnosed or relapsing eosinophilic granulomatosis with polyangiitis. A prospective, randomized, controlled, double-blind trial
Xavier Puéchal¹, Grégory Pugnet², Elisabeth Diot³, Claire de Moreuil⁴, Stéphane Jouneau⁵, Thomas Quemeneur⁶, Gabriel Baron⁷, Perrine Smets⁸, Antoine Néel⁹, Thomas Le Gallou¹⁰, Nicolas Noël¹¹, Yurdagül Uzunhan¹², Cloé Comarmond¹³, Geoffrey Urbanski¹⁴, Ygal Benhamou¹⁵, Alice Bérezné¹⁶, Arsène Mekinian¹⁷, Mohamed Hamidou⁹, Julien Campagne¹⁸, Noemie Abisror¹⁹, Benjamin Torreau³, Pascal Cohen²⁰, Loic Guillevin²⁰, Philippe Ravaud⁷ and Benjamin Terrier²¹, ¹Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, and Université Paris Cité, Paris ( ⁷⁵⁰¹⁴ ), Ile-de-France, France, ²CHU Toulouse Rangueil Service de Medecine Interne et Immunologie Clinique, Toulouse, France, ³Internal Medicine and Immunology, CHU Tours, Tours, France, ⁴CHU DE BREST, BREST, France, ⁵Respiratory Medicine, Université de Rennes ¹, CHU Pontchaillou, Rennes, France, ⁶Nephrology and Internal Medicine, CH Valenciennes, Valenciennes, France, ⁷Hôtel-Dieu, Université Paris Cité,, Paris, France, ⁸Internal Medicine, CHU Gabriel-Montpied, Clermont-Ferrand, France, ⁹Internal Medicine, CHU Hôtel-Dieu, Nantes, France, ¹⁰Internal Medicine and Clinical Immunology, CHU Rennes Sud, Rennes, ¹¹Internal Medicine and Clinical Immunology, CHU Bicêtre, Bicêtre, ¹²Respiratory Medicine, Hôpital Avicenne, Bobigny, France, ¹³Department of Internal Medicine, Lariboisière University Hospital, Université Paris Cité, Assistance Publique Hôpitaux de Paris, INSERM U⁹⁴², Paris, France, ¹⁴Internal Medicine and Clinical Immunology, CHU Angers, Angers, France, ¹⁵Internal Medicine, CHU Rouen, Rouen, France, ¹⁶Internal Medicine, CH, Annecy, Annecy, France, ¹⁷Department of Internal Medicine, Inflammation-Immunopathology-Biotherapy Department (DMU i³), Saint-Antoine University Hospital, ⁷⁵⁰¹² Paris, France, Paris, France, ¹⁸Internal Medicine, CH Robert Schuman, Metz, France, ¹⁹Internal Medicine, CHU Saint-Antoine,, Paris, France, ²⁰Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, Paris, France, ²¹Cochin Hospital, Paris, France
Background/Purpose: The eosinophilic granulomatosis with polyangiitis (EGPA) guidelines recommend considering maintenance therapy after remission to reduce the risk of relapse and toxicity, but data on…
Abstract Number: 1599 • ACR Convergence 2025
Cyclophosphamide versus Rituximab in the treatment of Anca-associated Vasculitis: Adverse events and Relapses
Fabricio Benavides Villanueva¹, Diana Prieto-Peña², Vanesa Calvo-Río³, Monica Renuncio-García⁴, Adrian Martin-Gutierrez⁵, Amparo Sanchez-Lopez⁶, Claudia Poo-fernandez⁷, maria Rodríguez-Vidriales⁸ and Ricardo Blanco³, ¹Division of Rheumatology, Hospital Universitario Marques de Valdecilla, IDIVAL, Immunopathology Group,Santander, Spain, Santander, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Spain, ³Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, ⁴Division of Immunology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Cantabria, Spain, ⁵Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Renedo de Piélagos, Spain, ⁶Division of Dermatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Cantabria, Spain, ⁷Division of Pneumology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Cantabria, Spain, ⁸Division of Nephrology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Cantabria, Spain
Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis include Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA), and Eosinophilic Granulomatosis with Polyangiitis (EGPA). EGPA presents a different pathogenic,…
Abstract Number: 0714 • ACR Convergence 2025
Factors Associated With Depression And Anxiety In ANCA-Associated Vasculitis Patients: Data From The Almenara Vasculitis Cohort
Alvaro Oyarce-Calderón¹, Allison Figueroa-Sánchez², Leonor León-Yaurimucha², Rocío Gamboa-Cárdenas³, Zoila Rodríguez-Bellido⁴, Risto Perich-Campos⁵, Graciela Alarcón⁶, Manuel Ugarte-Gil⁷ and Victor Pimentel-Quiroz⁸, ¹Hospital Nacional Guillermo Almenara Irigoyen, San Miguel, Lima, Peru, ²Universidad Científica del Sur, Lima, Peru, ³Universidad Científica del Sur, Lima, Peru, ⁴Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, Lima, Peru, ⁵Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, La Molina, Peru, ⁶The University of Alabama at Birmingham, Oakland, CA, ⁷Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Peru; Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, Lima, Peru, ⁸Universidad Científica del Sur, San Isidro, Peru
Background/Purpose: Depression and anxiety symptoms have been reported in 28% of patients suffering from vasculitides. However, in patients with ANCA-associated vasculitis (AAV), their frequency and…
Abstract Number: 2512 • ACR Convergence 2025
Contribution of the CALLY index at diagnosis to early prediction of all-cause mortality in patients with ANCA-associated vasculitis
Jang Woo Ha¹ and Sang-Won Lee², ¹Division of Rheumatology, Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Seodaemun-gu, Seoul, Republic of Korea, ²Yonsei university college of medicine, Seoul, South Korea
Background/Purpose: This study retrospectively investigated whether the initial C-reactive protein (CRP)-albumin-lymphocyte (CALLY) index at diagnosis can contribute to early prediction of all-cause mortality during follow-up…
Abstract Number: 1764 • ACR Convergence 2025
Development and Validation of a Simulation Model for Induction of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
Naomi Patel¹, Aaron Wu², Eli Miloslavsky³, Peter Merkel⁴, John Stone⁵, Hyon K. Choi⁶, Zachary Wallace³ and Emily Hyle², ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, ³Massachusetts General Hospital, Newton, MA, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Massachusetts General Hospital , Harvard Medical School, Concord, MA, ⁶MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA
Background/Purpose: Evaluating the effectiveness and safety profile of treatment strategies for the induction of remission of individuals with newly diagnosed AAV is important for guiding…
Abstract Number: 1597 • ACR Convergence 2025
Effectiveness and Safety of Rituximab Biosimilars in Small Vessel Vasculitis: a Systematic Literature Review
Caitlyn Kanters¹, Joo Young Lee², Christian Pagnoux³, Lillian Barra⁴, Jean-Paul Makhzoum⁵ and Arielle Mendel⁶, ¹McGill University, Montreal, Canada, ²Research institute of the McGill University Health Center, Montreal, QC, Canada, ³Mount Sinai Hospital, University Health Network, Toronto, and Canadian Vasculitis Research Network (CanVasc), Toronto, ON, Canada, ⁴Western University, London, ON, Canada, ⁵University of Montreal, Montreal, ⁶McGill University Health Centre, Montreal, Canada
Background/Purpose: To evaluate the safety and effectiveness of rituximab biosimilars in the treatment of small vessel vasculitis.Methods: The Medline, CINAHL, Cochrane, Embase and Web of…
Abstract Number: 0712 • ACR Convergence 2025
Effects of Bacterial Secretome on Nasal Epithelial Cell Gene Expression in ANCA-Associated Vasculitis
A. Nikolai von Krusenstiern¹, Eleni Bouziani², Sokratis Apostolidis², Li Hui Tan², Swetha Rajagopal³, Nicholas Bolden², Paul J. Planet³, Dylan Curry³, Elliot Friedman³, Noam A. Cohen⁴ and Rennie Rhee², ¹Hospital of the University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³Children’s Hospital of Philadelphia, Philadelphia, PA, ⁴University of Pennsylvania, Philadelphia
Background/Purpose: The nasal microbiome has been implicated as a contributor to relapse in ANCA-associated vasculitis (AAV). Previous research on nasal bacteria, particularly Staphylococcus aureus, has…
Abstract Number: 2513 • ACR Convergence 2025
Beyond Clinical trials in Eosinophilic Granulomatosis with Polyangiitis: A Systematic Review of effectiveness and safety data derived from real-world evidence of Mepolizumab 300 mg
Iñigo Rúa-Figueroa¹, Beatriz Velasco² and Maria Cid³, ¹Hospital de Gran Canaria Doctor Negrin, Las Palmas GC, Spain, ²GSK, Madrid, Spain, ³Department of Autoimmune Diseases (member of European Reference Network RITA), Hospital Clinic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is characterized by systemic necrotizing vasculitis affecting small and medium-sized vessels, and defined by the presence of eosinophilia, extravascular…
Abstract Number: 1693 • ACR Convergence 2025
Characterizing ANCA-specific B Cells in ANCA-associated Vasculitis
Laura van Dam¹, Mengrui Zhang¹, Shima Parsafar², Audra Horomanski³, Sajede Rasouli², Orr Sharpe², Jolijn van Leeuwen⁴, Tobias Lanz², Cees van Kooten⁴, Onno Teng⁵ and William H. Robinson³, ¹Stanford University, Stanford, CA, ²Stanford University, Stanford, ³Stanford University, Palo Alto, CA, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵Leiden University Medical Center, Leiderdorp, Netherlands
Background/Purpose: Anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) is a severe autoimmune disease, characterized by ANCAs targeting myeloperoxidase (MPO) or proteinase-3 (PR3). ANCA-specific B cells have…
Abstract Number: 1595 • ACR Convergence 2025
Subcordal Stenosis is a Glucocorticoid-Responsive Manifestation of Granulomatosis with Polyangiitis
Brendan Denvir¹, Brendan Antiochos², Philip Seo³ and Alexander Hillel³, ¹Johns Hopkins, Baltimore, MD, ²Johns Hopkins, CLARKSVILLE, MD, ³Johns Hopkins University, Baltimore, MD
Background/Purpose: Subglottic stenosis (SGS) is a recognized manifestation of granulomatosis with polyangiitis (GPA), occurring in 8–23% of patients. A distinct variant, identified in this study,…
Abstract Number: 0711 • ACR Convergence 2025
Analytical Performance of a Novel, Fully Automated Multiplexed Microarray Immunoassay Prototype for the Simultaneous Detection of Autoantibodies to GBM, PR3, and MPO: A Multicenter Evaluation
Natalia Swierczynska¹, Ruaridh Armour¹, Anthony Yau¹, Enn Rusi¹, Mark Hooper¹, Jason Sillitoe², Caroline Wilson², Paula Griffiths³, Tariq El-Shanawany³, Faye Sims⁴, Gerber Gomez⁵, Christian Fischer⁵, Michael Hausmann⁶ and Helen Laird¹, ¹Research & Development, AliveDx, Edinburgh, Scotland, United Kingdom, ²North East Innovation Lab, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, England, United Kingdom, ³Immunology Department, Laboratory Medicine, Swansea Bay University Health Board, UK. Cardiff and Vale UHB, Swansea, Wales, United Kingdom, ⁴Clinical Biochemistry and Immunology Department Peterborough City Hospital, North West Anglia NHS Foundation Trust, Peterborough, England, United Kingdom, ⁵Scientific & Medical Affairs, AliveDx Suisse SA, Eysins, Switzerland, ⁶AliveDx Suisse SA, Eysins, Switzerland
Background/Purpose: Anti-neutrophil cytoplasmic antibodies (ANCA), including those directed to myeloperoxidase (MPO) and proteinase 3 (PR3) as well as antibodies against anti-glomerular basement membrane (anti-GBM) are…
Abstract Number: 2511 • ACR Convergence 2025
The SHIPE index: A tertile-based approach to predict end-stage kidney disease in ANCA-associated vasculitis
HYUNSUE DO¹, Lucy Eunju Lee², Jang Woo Ha³, Jason Jungsik Song⁴, Yong-Beom Park⁵ and Sang-Won Lee⁶, ¹Kangwon national university hospital, Seoul, South Korea, ²Yonsei University, Seoul, Republic of Korea, ³Division of Rheumatology, Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Seodaemun-gu, Seoul, Republic of Korea, ⁴Yonsei University College of Medicine, Seoul, Republic of Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea, ⁶Yonsei university college of medicine, Seoul, South Korea
Background/Purpose: This study aimed to develop a simple, robust, and ethnoregion-specific index for predicting progression to end-stage kidney disease (ESKD) in Korean patients with antineutrophil…
Abstract Number: 1611 • ACR Convergence 2025
Effectiveness of Avacopan and Its Impact on Serum Calprotectin in MPA/GPA Patients Receiving Rituximab-Based Remission Induction: A Single-Center Study
Yusuke Ushio¹, Hiromi Shimada², Taichi Miyagi³, Koichi Sugihara², Mao Mizusaki², Rina Mino², Kanako Chujo³, Naoto Manabe³, Mayuko Wada², Shusaku Nakashima² and Hiroaki Dobashi², ¹Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita District, Kagawa, Japan, ²Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Kagawa, Japan, ³Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Japan
Background/Purpose: Avacopan, an oral C5a receptor antagonist, offers a promising glucocorticoid (GC)-sparing option for patients with microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA). Although…

1
2
3
…
23
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].